BCTXW
Get informed when a big investor buys or sells
+ FollowUndervalued by 3955.6% based on the discounted cash flow analysis.
| Market cap | $5.46 Million |
|---|---|
| Enterprise Value | $-1,417,372.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-62.95 |
| Beta | 2.03 |
| Outstanding Shares | 7,250,487 |
| P/E Ratio | -0.24 |
|---|---|
| PEG | -1.4 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.05 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.